Abiopharma

News list

FRACTYL HEALTH, INC. (GUTS)

SEC News
March 24, 2026, 20:03 UTC

(30% Negative) FRACTYL HEALTH, INC. (GUTS) Reports Q1 2026 Financial Results

Full text

News bot March 24, 2026, 8:04 p.m.

📋 FRACTYL HEALTH, INC. (GUTS) - Financial Results

Filing Date: 2026-03-24

Accepted: 2026-03-24 16:03:07

Event Type: Financial Results

Event Details:

FRACTYL HEALTH, INC. (GUTS) Reports the reporting period Financial Results FRACTYL HEALTH, INC. (GUTS) announced its financial results for the period ending the reporting period. Key Financial Highlights:

Revenue: 3
Net Income: Not disclosed
EPS: Not disclosed
Cash and equivalents: 81540
- expected in late Q4 2026
- expected in early Q4 2026
- targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease. Non-GAAP Financial MeasuresThis press release contains certain financial information that is not presented in conformity with U.S. generally accepted accounting principles (GAAP), including EBITDA and Adjusted EBITDA, which are non-GAAP financial measures as defined in Regulation G promulgated under the Securities Exchange Act of 1934

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2025	2024	Change ($)	Change (%)
Revenue	3.00	3.00	$0.00	+0.00%
Operating Expenses Selling General Administrative	4.93K	22.28K	$-17.35K	-77.86%
Operating Expenses Loss From Operations	25.21K	96.82K	$-71.61K	-73.96%
Other Income Expense Net Total Other Income Expense	240.00	44.14K	$-43.90K	-99.46%
Revenue	3.00	3.00	$0.00	+0.00%
Selling, General & Administrative	4.93K	22.28K	$-17.35K	-77.86%
Loss from Operations	25.21K	96.82K	$-71.61K	-73.96%
Interest Income	726.00	1.54K	$-814.00	-52.86%
Total Other Income/(Expense)	240.00	44.14K	$-43.90K	-99.46%
Net Loss	24.97K	140.95K	$-115.98K	-82.29%

💼 Business Developments:

No business developments data available.

Structured Data:

Company Name: FRACTYL HEALTH, INC.
Ticker Symbol: GUTS